Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, announces the appointment of Mads Bodenhoff as Chief Financial Officer and Vice President.
Mads Bodenhoff brings a strong track record in finance and accounting, IT, legal, M&A, and sustainability to Xellia’s Leadership Team. He joins Xellia from Novozymes, where he held a number of senior managerial positions over a 14 year period, most recently as Vice President, Corporate Finance. Prior to this, Mads worked at Novo Nordisk and Arthur Andersen and has gained substantial international experience, working in both China and the US. Mads has a Master's Degree in Accounting, Tax and Auditing from Copenhagen Business School and is a State-Authorised Public Accountant.
Carl-Åke Carlsson, CEO Xellia said: “I am pleased to welcome Mads to Xellia. He is joining us at a pivotal time in our business as we roll out our ambitious global expansion plans to scale-up and extend the range of products we offer our over 500 pharmaceutical customers worldwide. Mads’ skills and expertise will contribute significantly to Xellia’s future success.”
Mads succeeds Kennet Lundberg who leaves Xellia to pursue other opportunites. Thanking Kennet Lundberg for his contribution, Carl-Åke Carlsson said: "Over the past five years Kennet has played a key role in the successful transformation of our business from an active pharmaceutical ingredient (API) manufacturer to a specialty pharmaceutical company focused on anti-infective products. We wish Kennet every success with his future ventures."
Xellia began the first stage of its global growth strategy in May, investing to expand its Product and Innovation R&D Centre of Excellence in Zagre, Croatia. In July the Company announced the acquisition of Fresenius Kabi’s dedicated lyophilised (freeze-dried) vial manufacturing facility in Raleigh, North Carolina. This was Xellia’s first site in the USA, a key market for the Company.
For more information, please contact:
Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
Tel.: +45 32 64 55 00
Instinctif Partners (media relations)
Melanie Toyne Sewell / Eileen Paul / Jen Lewis
Tel: +44 (0) 20 7457 2029 / +44 (0)1260 296 500
E-mail: xellia@instinctif.com